Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Cellular Senescence: Friend or Foe to Respiratory Viral Infections?

William J. Kelley, Rachel L. Zemans, Daniel R. Goldstein
European Respiratory Journal 2020; DOI: 10.1183/13993003.02708-2020
William J. Kelley
1Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
2Program in Immunology, University of Michigan, Ann Arbor, MI, USA
3Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel L. Zemans
1Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
2Program in Immunology, University of Michigan, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel R. Goldstein
1Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
2Program in Immunology, University of Michigan, Ann Arbor, MI, USA
3Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel R. Goldstein
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Cellular senescence permanently arrests the replication of various cell types and contributes to age-associated diseases. In particular, cellular senescence may enhance chronic lung diseases including chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. However, the role cellular senescence plays in the pathophysiology of acute inflammatory diseases, especially viral infections, is less well-understood. There is evidence that cellular senescence prevents viral replication by increasing antiviral cytokines, but other evidence shows that senescence may enhance viral replication by downregulating antiviral signalling. Furthermore, cellular senescence leads to the secretion of inflammatory mediators, which may either promote host defense or exacerbate immune pathology during viral infections. In this perspective, we summarise how senescence contributes to physiology and disease, the role of senescence in chronic lung diseases, and how senescence impacts acute respiratory viral infections. Finally, we develop a potential framework of how senescence may contribute, both positively and negatively, to the pathophysiology of viral respiratory infections, including SARS-CoV-2.

Abstract

Senescence associates with fibrotic lung diseases. Emerging therapies to reduce senescence may treat chronic lung diseases, but the impact of senescence during acute respiratory viral infections is unclear and requires future investigation.

Cellular Senescence: Definition and Evolutionary Origins

Cellular senescence describes a state of permanent replicative arrest in normally-proliferative cells. Originally discovered in vitro in human fibroblasts by Hayflick and colleagues, the concept of cellular senescence was met with controversy [1, 2]. Initially, some investigators were skeptical and believed that senescence was an in vitro artefact. But with accumulating in vivoevidence including the presence of senescence in aged human skin cells [3], scientists accepted senescence as a true biological phenomenon. Senescence is now known to contribute to a variety of age-related diseases including: type 2 diabetes, obesity, atherosclerosis, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and others [4–6]. With aging, our cells continually divide, shorten their telomeres, accumulate mutations and DNA damage, all of which ultimately increase the likelihood of oncogenesis [7, 8].

Under typical physiological conditions, oncogene-induced senescence may hinder the development of certain cancers including lymphoma [9] and prostate cancer [10] and improve patient response to chemotherapeutics [11]. Senescent cells may also upregulate phagocytic receptors, therefore increasing phagocytosis and immune surveillance to reduce cancer development. Additionally, senescent cells secrete extra-cellular matrix proteins and growth factors that contribute to some restorative processes including wound healing [12]. Similarly, senescent cells have been shown to reduce liver [13, 14] and pancreatic fibrosis and promote wound healing [15]. Furthermore, fibroblasts made senescent by the matricellular protein CCN1 limit fibrosis in cutaneous wounds [16]. Senescent cells may also contribute to tissue growth during embryonic development [17, 18]. In summary, senescence likely evolved to respond to the acute stress of organ development, mitigate against the acute effects of damaged cells to return tissue to homeostasis, and ultimately to reduce the development of cancer [19].

With improvements in public health in the 20th century and subsequent extensions of human life-span, senescence has emerged as a contributing factor to several chronic age-associated diseases. Indeed, we now recognise senescence as one of the key hallmarks of aging, as senescence occurs as we age naturally [20]. Although a key hallmark of aging, senescence is not sufficient for all aging phenotypes [20], and senescence can occur in young hosts as a result of acute stressors (see next section). However, the importance of senescence in acute inflammatory conditions, especially respiratory viral infections, is less well appreciated. Here, we first briefly review how senescence contributes to chronic inflammation, particular in the context of lung diseases, and emerging therapies to treat senescence. Then, we discuss the role senescence plays in acute respiratory viral infections and implications for such a role during infection with SARS-CoV-2.

What leads to senescence and the resulting Senescence Associated Secretory Phenotype (SASP)

Senescence can arise from both repeated cellular division and cellular stressors. Replicative senescence arises from repeated cellular divisions, such as occur naturally when we age. Stress-induced senescence arises from cellular stressors such as increases in reactive oxygen species, which correlate with DNA damage [21, 22]. These can occur from irradiation, chemotherapeutic agents, chronic exposure to pollutants (cigarette smoke), exposure to pathogens, and some forms of accelerated aging syndromes, such as progeria [23–26]. Therefore, cells from both young and aged hosts can exhibit senescence. As previously mentioned, senescence is one of the key biological hallmarks of aging and contributes to aging via inflammation, tissue exhaustion and impaired stem cell renewal [20].

Importantly, stem cells can become senescent as we age. Specifically, mesenchymal stem cells isolated from older humans (>70 years of age) exhibit senescence including reduced proliferation and a chronic inflammatory secretome, which impairs hematopoietic stem and progenitor cell (HSPC) replication and increases HSPC MCP1 and IL-8 expression [27]. Consequently, senescent mesenchymal stem cells are not able to be used in stem cell therapeutics due to their inability to proliferate and their reduced expression of pro-angiogenic factors [28]. Additionally, senescent neural progenitor cells contribute to the development of multiple sclerosis [29]. Specifically, senescent neural progenitor cells inhibit oligodendrocyte differentiation and contribute to demyelination via the production of high mobility group box-1, which suppresses oligodendrocyte progenitor cell proliferation and induces pro-inflammatory transcriptomic changes in oligodendrocyte progenitor cells [29]. Thus, senescent stem cells impair wound healing, promote the development of inflammatory diseases, and limit the use of stem cells in therapeutic applications.

In addition to the direct effects on stem cells, there are two potential pathways by which senescence may contribute to disease. First, senescent cells stop proliferating, which prevents tissue repair after injury. Second, as senescent cells accumulate, they produce, for unclear reasons, low levels of inflammatory mediators, a phenomenon which has been termed “inflammaging” particularly when evident in older people [30–33]. Senescent cells contribute to chronic inflammation via the senescence-associated secretory phenotype (SASP), the collective term for the proinflammatory chemokines and cytokines released by senescent cells [34]. The SASP is comprised of a number of proinflammatory molecules, including TNF-α, IL-1α/β, IL-6, IL-8, CCL-2, and others [35–38]. The SASP seems to be a double-edged sword. On the one hand, long-term exposure of SASP inflammatory mediators can lead to over-recruitment of damaging immune cells, resulting in chronic inflammatory diseases and even fibrosis [5, 39]. On the other hand, in the short term, the SASP promotes wound healing that is required to respond to acute cellular damage [12, 13, 40].

Importantly, the specific characteristics of the SASP may be dependent on the cell type and the mechanism of senescence induction [41]. For example, the SASP associated with fibroblasts contains significantly more SASP factors than the SASP associated with renal epithelial cells [41]. Some SASP pathways are shared between fibroblasts and epithelial cells, while some pathways are distinct to each cell type. Specifically, senescent epithelial cells upregulate pathways associated with protein translation and degradation; senescent fibroblasts upregulate pathways associated with apoptosis, ROS generation, and extracellular matrix reorganisation; and both senescent fibroblasts and epithelial cells upregulated pathways associated with vesicle transport, metabolism, and detoxification [41]. Note that in this particular study, senescence was induced in vitro in human cell lines. However, the investigators identified several secreted proteins in their in vitro models which were also found in the plasma of older subjects, suggesting that the findings of the study could be translatable in vivo. In vitro senescence is associated with the accumulation of sterile inflammatory mediators, like HMBG1, a nuclear protein that can activate inflammation [41]. Furthermore, SASP mediators such as TNF-α can induce senescence, which likely further enhances the SASP in a feed-forward loop [42]. Thus, one of the mechanisms by which senescence leads to chronic inflammation may be by the release of sterile inflammatory mediators, also known as damage associated molecular patterns. Additionally, the SASP is temporally dynamic and the dynamics change depending on the cell type [43]. Overall, senescence induces distinct cellular programs that lead to the secretion of proteins that promote chronic inflammation. Clearly, dissecting the physiological from the pathophysiological aspects of senescence will be required for the development of effective therapies targeting senescence to alleviate age-related diseases.

Senescence-Targeted Therapeutics

Recently, there has been a focus on alleviating the negative effects of cellular senescence using senescence-targeted therapeutics. Such therapeutics fall into two primary categories: SASP inhibition and senescent cell removal. SASP inhibition involves downregulating various components of the SASP, or inhibiting the inflammatory pathways that SASP factors engages, with the goal of ameliorating the deleterious effects of SASP factors. This strategy is successful in a variety of contexts. For example, Janus kinase (JAK) inhibition alleviates inflammation, both locally in the adipose tissue and systemically, and reduces frailty in aged mice [44]. Evidence that the SASP may be related to the pathogenesis of age-related diseases comes from reports that pharmacological tools to inhibit NF-κB signalling ameliorate age-related diseases. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin selectively reduces NF-κB signalling (a major inflammation signalling hub) in senescent cells through suppression of IL-1α activity, reduces age-associated cognitive decline, improves immune function in older people, and increases the lifespan of mice [45–49]. Metformin, a commonly-used type-2 diabetes drug, also inhibits NF-κB resulting in improved lifespan in mice, and reduced all-cause mortality and age-related disease in humans [50–53]. However, inhibiting the SASP results in off-target side effects including neutrophilia, nephrotoxicity, and changes in T cell phenotype due to the myriad of interconnected pathways involved in inflammatory signalling [45] Specifically, inhibition of the NF-κB pathway, either by genetic deletion or small-molecule inhibition, has been shown to inhibit T cell, B cell, and lymphoid progenitor cell development [55]; induce apoptosis of thymocytes, B cells, and macrophages [56, 57]; impair lymphocyte growth and cytokine production [58]; and potentially increase susceptibility to various infections [59]. All of these strategies target inflammatory pathways that senescence may activate but do not specifically target senescent cells.

Removing senescent cells involves directly targeting senescent cells by inducing apoptosis. The first therapeutics designed to directly kill senescent cells (termed “senolytics”) targeted the BCL-2 protein family, an anti-apoptotic pathway that is involved in oncogenesis. The most widely-studied therapeutic strategy, however, is a combination therapy involving the administration of the tyrosine kinase inhibitor dasatinib (D) and the flavonoid quercetin (Q). The “D+Q” combination reduces senescent cell burden and improves health span and lifespan in aged mice, reduces vascular stiffening, improves vasomotor function, and improves pulmonary function in murine models of pulmonary fibrosis [60–64]. Indeed, preliminary clinical trials have shown evidence that D+Q treatment reduces senescent cell burden and may improve physical function in patients with pulmonary fibrosis [65, 66]. However, we still do not fully appreciate the potential off-target effects of senolytic agents such as D+Q, as well as their mechanism of action in humans, which will require elucidation before they can be used to treat age-related diseases.

Cellular Senescence in the Lung

In addition to replicative senescence induced by aging, several other factors contribute to the development of stress-induced senescence in the lung, including radiation therapy, smoking, mechanical ventilation, and chronic use of supplemental oxygen (fig. 1). [24, 67–70], which supports the concept that other processes besides natural aging lead to senescence. Increasing numbers of senescent cells correlate with increasing concentrations of SASP factors. This is supported by the finding that the cytokines IL-6 and IL-10 and neutrophil counts are elevated in the bronchoalveolar lavage fluid (BALF) of older (note: “older” is designated>65 years of age in this review) donors, which may exhibit senescence in the lung [71]. This age-related phenotype correlates with age-related lung diseases such as COPD. Furthermore, patients with COPD exhibit increased concentrations of senescent type II alveolar epithelial cells (AECs) [72, 73] and lung fibroblasts [74], as well as elevated levels of inflammatory cytokines including IL-1β, IL-6, IL-8, IL-10, and CCL-2 [75–78]. While a causal link is difficult to prove, the low-grade inflammation caused by lung senescent cells may contribute to the development of and/or exacerbates COPD. Similar patterns of elevated inflammatory cytokine levels and senescent cells are linked to other chronic lung diseases such as asthma [79, 80]. Furthermore, the exuberant wound healing response mediated by SASP factors, combined with the inability to effectively repair tissue due to cessation of proliferation, and possibly impairments in stem cell functions, may promote fibrosis and contribute to idiopathic pulmonary fibrosis [81–84]. Thus, lung senescent cells likely contribute to the severity of many chronic lung diseases.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Causes of lung senescence. Many factors contribute to the induction of senescence within lung cells. Apart from natural aging, other sources of senescence include chronic exposure to pollutants and cigarette smoke, chemotherapy, ionising radiation, respiratory viral infections, and the use of mechanical ventilators. Each of these sources may induce senescence to varying degrees, and it remains unclear whether senescence originating from different sources and in different cells contributes to pathology similarly or differently.

The potential contributions of lung cellular senescence in acute respiratory conditions remain unclear. In a murine model of acute lung injury (ALI), senescent alveolar macrophages exhibit enhanced activation and secretion of proinflammatory cytokines, resulting in enhanced disease severity [85]. Similarly, aged mice, which likely exhibit increased lung senescence, also exhibit enhanced lung permeability and increased levels of reactive oxygen species in response to an LPS challenge, which is linked to deficient Nox4 (a ROS-generating mitochondrial protein) ubiquination [86]. Additionally, older trauma patients are significantly more likely to develop acute respiratory distress syndrome (ARDS), and older patients with ARDS exhibit a higher mortality rate [87]. However, in all of these studies the pathological role of senescence was not tested. Also, a recent study found that lung cellular senescence protects against lung injury induced by mechanical ventilation by preventing apoptosis [68]. Clearly, the impact of cellular senescence on acute lung conditions requires future investigation.

Cellular Senescence and Respiratory Viral Infections

The COVID-19 pandemic continues to claim thousands of lives every day and disproportionately affects older people. Given this, how cellular senescence impacts the host response to acute respiratory viral infections is particularly relevant. Older people experience increased susceptibility to respiratory viruses such as influenza, respiratory syncytial virus (RSV), SARS, and now SARS-CoV-2 [88–92]. With COVID-19, the disease that results from SARS-CoV-2 infection, older people are ∼20 fold more likely to die than younger people [93]. This effect has been partially attributed to defects associated with the aging of the immune system, termed “immunosenescence”, which is distinct from classical cellular senescence as defined above and reviewed elsewhere [94–96]. Briefly, immunosenescence has pleiotropic effects on the immune system including: i) a decrease in the proliferative capacity of hematopoietic stem cells; ii) dysregulation of innate immunity; iii) reduced numbers of naïve T cells with thymic involution; iv) accumulation of memory T and B cells; and v) a general decline in both T and B cell function [94, 97–99]. Specifically, both CD4+ and CD8+ T cells from aged hosts (e.g., rodents and humans) exhibit a reduced proliferative capacity associated with downregulation of surface costimulatory receptors, CD27 and CD28, which is accompanied by shortened telomeres. Collectively, these alterations within the immune system with aging result in an impaired ability to fight viral infections and lead to reduced vaccine efficiency [90]. In addition to natural aging, chronic viral infections (e.g., HIV and cytomegalovirus infection) also induce a phenotype of reduced T cell function (i.e., reduced proliferation and cytokine secretion) that shares features with immunosenescence [100, 101]. Although aging of the immune system impairs host defense to acute respiratory viral infections [90], the role that cellular senescence of lung cells play in the pathophysiology of acute respiratory viral infections is not well-understood. Clearly, older people are highly susceptible to viral infections due to a myriad of effects exerted by aging on the immune system. But how much of this is contributed by cellular senescence, as defined above, remains to be elucidated. Indeed, it is not clear if cellular senescence, due to natural aging or due to an age-independent stressor, promotes or prevents acute respiratory viral infections. To the best of our knowledge, there are only a few studies on the role of cellular senescence and acute respiratory viral infections, with some showing contrasting results.

There are studies which claim that cellular senescence enhances anti-viral immunity [102], which is biologically plausible, as SASP factors, which includes chemokines (e.g., CxCL1/2) that recruit innate immune cells like neutrophils may augment host defense to viral infections [103]. Specifically, one study showed that cellular senescence inhibits vesicular stomatis virus (a RNA virus) replication in both primary murine fibroblasts with replication-induced senescence, and in a tumor cell line with chemotherapy-induced senescence [102], possibly due to SASP factors, including the release of type I interferons (IFN), important anti-viral cytokines [104]. Additionally, mice that were induced to exhibit senescence within the lung via bleomycin exposure were more resistant to vesicular stomatis virus infection in vivo than mice that were not exposed to bleomycin. This is compatible with in vitro studies that found that type I IFN, in addition to other SASP components such as IL-6 and IL-8, induces cellular senescence [105, 106], and vice versa. Additionally, cellular fusion caused by the fusogenic measles virus induces cellular senescence, including the release of SASP factors, in fibroblasts in vitro [107], although the in vivo implications of this finding are unclear. Collectively, these studies suggest that senescence that is induced acutely by viruses may be a part of the body's antiviral immune response [108, 109]. This defense mechanism may have evolved to allow virus-infected cells to secrete SASP factors to limit viral replication in neighboring cells and ultimately viral spread throughout the lung. Furthermore, the SASP factors, may enhance host defense by promoting immune cell recruitment to the lung. But if these SASP factors are produced exuberantly, immune pathology could ensue (fig. 2). Finally, some viruses, including human papillomavirus and hepatitis B, have evolved machinery specifically to overcome cellular senescence [110, 111], suggesting that senescence plays a role in antiviral defense in some contexts.

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

Hypothesis: Senescence may play divergent roles during acute respiratory viral infections depending on host resilience. In young hosts, senescence induced by viral infection may play a positive role by recruiting neutrophils (PMNs) and other immune cells via the senescence associated secretory phenotype (SASP), resulting in viral clearance and tissue repair. In aged or vulnerable hosts, however, senescence induced by viral infection, in addition to the senescence already present, may tip the balance towards pathology. This pathology is characterised by an exuberant immune response, including high levels of SASP including cytokines and chemokines, causing exaggerated recruitment of PMNs and other immune cells, resulting in lung tissue damage.

However, there is evidence that senescence contributes to the pathophysiology of respiratory viral infections. RSV induces DNA damage resulting in senescence in both mononuclear cells and lung epithelia in young mice [25], which enhances airway tissue remodelling (exhibited by a loss of ciliated cells and an increase in secretory cells [112]), potentially leading to permanent tissue damage and fibrosis. Furthermore, senescent cells may promote viral replication. For example, the influenza virus replicates more efficiently within senescent human bronchial epithelial cells than non-senescent cells [113]. Similar results are found with varicella zoster virus, a herpes virus, which replicates more efficiently in senescent human dermal fibroblasts than non-senescent cells [113]. A potential explanation for this phenomenon may be that senescence induced by these viruses downregulates the antiviral type I IFN program, including key signalling proteins, e.g., STING and IRF-3, upon infection in vitro with varicella virus [113]. This downregulation could lead to reduced secretion of antiviral IFNs, promoting viral replication. Whether this occurs in vivo is not known, however. Differences between this study and the contrasting one above, which found that senescence reduces replication of vesicular stomatis virus [102], could be due to the different viruses employed (i.e., vesicular stomatitis versus influenza, varicella), different cell types (MCF7, A549 cell lines and primary murine embryo fibroblast cells in the vesicular stomatitis study versus primary human bronchial epithelial cells and primary human dermal fibroblasts in the influenza/varicella study), and different approaches to induce senescence (replicative senescence and bleomycin in the vesicular stomatitis study versus only replicative senescence in the influenza/varicella study). Clearly, future studies are required to determine if senescence is harmful or beneficial to pathologically relevant respiratory viruses.

Cellular Senescence: Friend or Foe in Respiratory Viral Infections?

The overall impact of cellular senescence on acute respiratory viruses may depend on host resilience factors (fig. 2). For example, the SASP may have evolved to enhance host defense by increasing the recruitment of immune cells. This is likely beneficial in resilient young hosts who do not overproduce SASP factors. Indeed, initial neutrophil recruitment to the lung is critical to host defense to influenza infection [103]. But in vulnerable aged hosts, the SASP factors may be produced at pathologically high levels to promote immune pathology. Specifically, CXCL-1, CXCL-2, and IL-17, are increased in the lungs of aged mice even before viral infection, and accompany excessive neutrophil recruitment into the lung to enhance mortality during acute influenza infection [103]. In this study, senescent alveolar epithelial cells were found to produce more neutrophil chemoattractants and thus increase neutrophil chemotaxis. Similarly, aged rhesus macaques express higher levels of CCL-2, IL-6, and IL-8 in the lungs in response to influenza infection, suggesting an exaggerated innate immune response [114]. Based on these studies, inhibiting the SASP or reducing lung senescent cells might be beneficial in aged hosts infected with acute respiratory viral infections. However, formal investigation is required to determine if removing senescent cells prior to infection is sufficient, or if treatment during infection is required. Importantly, vulnerable hosts, including older people and people with comorbidities such as diabetes, are more susceptible to SARS-COV-2, which emerging studies suggest is due to the cytokine storm and excessive neutrophil effector functions within the lung [90].

We still do not know whether senescent cells in the lung ultimately increase or reduce viral replication. Respiratory viruses may “hijack” the senescent machinery within the infected cell to downregulate the IFN pathway to promote viral packaging and ultimately enhance viral replication within the cell. It is not clear yet if this occurs in vivo and, if so, what underlying mechanisms are involved. In contrast, activation of the senescence machinery within a virally-infected cell may be a damage response mechanism that leads to the secretion of antiviral cytokines to limit viral replication, an issue that also requires future investigation. Alternatively, senescence may simply be a side-effect of viral infection; during and after infection, various inflammatory cytokines are upregulated, resulting in the induction of senescence in infected cells.

Conclusions

Ultimately, the impact of senescence on respiratory viral infections requires further investigation before firm conclusions can be drawn. The impact of senescence on both viral replication and mortality in respiratory viral infections such as influenza, RSV, SARS, and SARS-CoV-2 should be comprehensively studied to determine if senescence-targeted therapies, such as senolytics, might be effective, or not, at reducing the age-dependent mortality of acute respiratory viral infections. Furthermore, it remains unclear as to whether senescence associated with natural aging results in the same impact on respiratory viral infections as stress-induced senescence; thus, a direct comparison between such models of senescence is warranted. For example, do mice with bleomycin-induced lung senescence exhibit a similar phenotype and mortality response as aged mice when infected with influenza, RSV, or other respiratory viral infections?

Additionally, the effectiveness (or lack thereof) of senescence-targeted therapies broadly, and senolytics, specifically, has yet to be assessed during respiratory viral infections. While senolytics have shown some therapeutic efficacy in preclinical models of chronic illnesses such as pulmonary fibrosis, it is unknown if these effects translate to more acute conditions, and if so, how the therapeutic regimen might be optimised. For example, it may be that prophylactic senolytic treatment is effective at reducing the total senescent cell concentration in the lungs, thereby improving disease outcomes, while post-infection treatment may not be as effective, especially if removing senescent cells impairs wound healing and reduces inflammation resolution. Examining these outstanding questions will shed light on how senescence impacts our host defense to respiratory viruses, which will continue to disproportionately impact older people for the foreseeable future, particularly during the current COVID-19 pandemic. Thus, moving forward, significant research efforts focused on the interactions between cellular senescence and respiratory viral infections are clearly warranted.

Footnotes

  • Support Statement: WJK is supported by the National Institutes of Health Training Grant T32HL007622. DRG is supported by NIH awards: R01AG028082, R01HL127687, R01AI13834, K07AG050096 and T32AG062403. RLZ is supported by NIH awards: R01HL147920, R01HL131608, R01AG028082. National Institute on Aging; DOI: http://dx.doi.org/10.13039/100000049; Grant: R01AG028082.

  • Author contributions: All authors were involved in the design of the review. WJK wrote the first draft, which was then edited by DRG and RLZ. All authors approved the final manuscript.

  • NA

  • Data availability: NA

  • Conflict of interest: Dr. Kelley has nothing to disclose.

  • Conflict of interest: Dr. Zemans has nothing to disclose.

  • Conflict of interest: Dr. Goldstein has nothing to disclose.

  • Received July 9, 2020.
  • Accepted September 30, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Hayflick L,
    2. Moorhead PS
    . The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 25: 585–621. doi:10.1016/0014-4827(61)90192-6
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Hayflick L
    . The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37: 614–636. doi:10.1016/0014-4827(65)90211-9
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Dimri GP,
    2. Lee X,
    3. Basile G, et al.
    A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92: 9363–9367. doi:10.1073/pnas.92.20.9363
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Morty RE,
    2. Prakash YS
    . Senescence in the lung: Is this getting old? Am J Physiol Lung Cell Mol Physiol 2019; 316: L822–L825. doi:10.1152/ajplung.00081.2019
    OpenUrl
  5. ↵
    1. He S,
    2. Sharpless NE
    . Senescence in Health and Disease. Cell 2017; 169: 1000–1011. www.dx.doi.org/10.1016/j.cell.2017.05.015. doi:10.1016/j.cell.2017.05.015
    OpenUrlCrossRefPubMed
  6. ↵
    1. Childs BG,
    2. Durik M,
    3. Baker DJ, et al.
    Cellular senescence in aging and age-related disease: From mechanisms to therapy. Nat Med 2015; 21: 1424–1435. doi:10.1038/nm.4000
    OpenUrlCrossRefPubMed
  7. ↵
    1. Campisi J
    . Aging, Cellular Senescence, and Cancer. Annu Rev Physiol 2013; 75: 685–705. doi:10.1146/annurev-physiol-030212-183653
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Sager R
    . Senescence as a mode of tumor suppression. Environ Health Perspect 1991; 93: 59–62. doi:10.1289/ehp.919359
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Braig M,
    2. Lee S,
    3. Loddenkemper C, et al.
    Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005; 436: 660–665. doi:10.1038/nature03841
    OpenUrlCrossRefPubMed
  10. ↵
    1. Chen Z,
    2. Trotman LC,
    3. Shaffer D, et al.
    Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436: 725–730. doi:10.1038/nature03918
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Schmitt CA,
    2. Fridman JS,
    3. Yang M, et al.
    A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109: 335–346. doi:10.1016/S0092-8674(02)00734-1
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Demaria M,
    2. Ohtani N,
    3. Youssef SA, et al.
    An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA. Dev Cll 2014; 31: 722–733. doi:10.1016/j.devcel.2014.11.012
    OpenUrl
  13. ↵
    1. Krizhanovsky V,
    2. Yon M,
    3. Dickins RA, et al.
    Senescence of Activated Stellate Cells Limits Liver Fibrosis. Cell 2008; 134: 657–667. doi:10.1016/j.cell.2008.06.049
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Kim K-H,
    2. Chen C-C,
    3. Monzon RI, et al.
    Matricellular Protein CCN1 Promotes Regression of Liver Fibrosis through Induction of Cellular Senescence in Hepatic Myofibroblasts. Mol Cell Biol 2013; 33: 2078–2090. doi:10.1128/MCB.00049-13
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Fitzner B,
    2. Müller S,
    3. Walther M, et al.
    Senescence determines the fate of activated rat pancreatic stellate cells. J Cell Mol Med 2012; 16: 2620–2630. doi:10.1111/j.1582-4934.2012.01573.x
    OpenUrlPubMed
  16. ↵
    1. Jun JI,
    2. Lau LF
    . The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat Cell Biol 2010; 12: 676–685. doi:10.1038/ncb2070
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Muñoz-Espín D,
    2. Cañamero M,
    3. Maraver A, et al.
    Programmed cell senescence during mammalian embryonic development. Cell 2013; 155: 1104. doi:10.1016/j.cell.2013.10.019
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Storer M,
    2. Mas A,
    3. Robert-Moreno A, et al.
    Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell 2013; 155: 1119. www.dx.doi.org/10.1016/j.cell.2013.10.041. doi:10.1016/j.cell.2013.10.041
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. McHugh D,
    2. Gil J
    . Senescence and aging: Causes, consequences, and therapeutic avenues. J Cell Biol 2018; 217: 65–77. doi:10.1083/jcb.201708092
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. López-otín C,
    2. Blasco MA,
    3. Partridge L, et al.
    The Hallmarks of Aging. Cell 2013; 153: 1194–1217. doi:10.1016/j.cell.2013.05.039
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Ksiazek K,
    2. Mikula-Pietrasik J,
    3. Olijslagers S, et al.
    Vulnerability to oxidative stress and different patterns of senescence in human peritoneal mesothelial cell strains. Am J Physiol Regul Integr Comp Physiol 2009; 296: 374–382. doi:10.1152/ajpregu.90451.2008
    OpenUrl
  22. ↵
    1. Weyemi U,
    2. Lagente-Chevallier O,
    3. Boufraqech M, et al.
    ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene 2012; 31: 1117–1129. doi:10.1038/onc.2011.327
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Van Deursen JM
    . The role of senescent cells in ageing. Nature 2014; 509: 439–446. doi:10.1038/nature13193
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Nyunoya T,
    2. Monick MM,
    3. Klingelhutz A, et al.
    Cigarette smoke induces cellular senescence. Am J Respir Cell Mol Biol 2006; 35: 681–688. doi:10.1165/rcmb.2006-0169OC
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Martínez I,
    2. García-Carpizo V,
    3. Guijarro T, et al.
    Induction of DNA double-strand breaks and cellular senescence by human respiratory syncytial virus. Virulence 2016; 7: 427–442. doi:10.1080/21505594.2016.1144001
    OpenUrlCrossRef
  26. ↵
    1. Wheaton K,
    2. Campuzano D,
    3. Ma W, et al.
    Progerin-Induced Replication Stress Facilitates Premature Senescence in Hutchinson-Gilford Progeria Syndrome. Mol Cell Biol 2017; 37: 1–18. doi:10.1128/MCB.00659-16
    OpenUrlCrossRef
  27. ↵
    1. Gnani D,
    2. Crippa S,
    3. della Volpe L, et al.
    An early-senescence state in aged mesenchymal stromal cells contributes to hematopoietic stem and progenitor cell clonogenic impairment through the activation of a pro-inflammatory program. Aging Cell 2019; 18: e12933. doi:10.1111/acel.12933
    OpenUrl
  28. ↵
    1. Liu J,
    2. Ding Y,
    3. Liu Z, et al.
    Senescence in Mesenchymal Stem Cells: Functional Alterations, Molecular Mechanisms, and Rejuvenation Strategies. Front Cell Dev Biol 2020; 8: 258. doi:10.3389/fcell.2020.00258
    OpenUrl
  29. ↵
    1. Nicaise AM,
    2. Wagstaff LJ,
    3. Willis CM, et al.
    Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis. Proc Natl Acad Sci USA 2019; 116: 9030–9039. doi:10.1073/pnas.1818348116
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Sanada F,
    2. Taniyama Y,
    3. Muratsu J, et al.
    Source of Chronic Inflammation in Aging. Front Cardiovasc Med 2018; 5: 1–5. doi:10.3389/fcvm.2018.00012
    OpenUrlPubMed
    1. Baylis D,
    2. Bartlett DB,
    3. Patel HP, et al.
    Understanding how we age: insights into inflammaging. Longev Heal 2013; 2: 1–8. doi:10.1186/2046-2395-2-1
    OpenUrl
    1. Franceschi C,
    2. Capri M,
    3. Monti D, et al.
    Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007; 128: 92–105. doi:10.1016/j.mad.2006.11.016
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Piber D,
    2. Olmstead R,
    3. Cho JHJ, et al.
    Inflammaging: Age and Systemic, Cellular, and Nuclear Inflammatory Biology in Older Adults. J Gerontol A Biol Sci Med Sci 2019; 74: 1716–1724. doi:10.1093/gerona/glz130
    OpenUrl
  32. ↵
    1. Campisi J
    . Aging, Cellular Senescence, and Cancer. Annu Rev Physiol 2013; 75: 685–705. doi:10.1146/annurev-physiol-030212-183653
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Tchkonia T,
    2. Zhu Y,
    3. van Deursen J, et al.
    Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 2013; 123: 966–972. doi:10.1172/JCI64098
    OpenUrlCrossRefPubMedWeb of Science
    1. Freund A,
    2. Orjalo AV,
    3. Desprez PY, et al.
    Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med 2010; 16: 238–246. doi:10.1016/j.molmed.2010.03.003
    OpenUrlCrossRefPubMedWeb of Science
    1. Coppé JP,
    2. Patil CK,
    3. Rodier F, et al.
    Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008; 6: 2853–2868. doi:10.1371/journal.pbio.0060301
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. Kumar S,
    2. Millis AJT,
    3. Baguoni C
    . Expression of interleukin 1-inducible genes and production of interleukin 1 by aging human fibroblasts. Proc Natl Acad Sci USA 1992; 89: 4683–4687. doi:10.1073/pnas.89.10.4683
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Childs BG,
    2. Durik M,
    3. Baker DJ, et al.
    Cellular senescence in aging and age-related disease: from mechanisms to therapy Bennett. Nat Med 2015; 21: 1424–1435. doi:10.1038/nm.4000
    OpenUrlCrossRefPubMed
  36. ↵
    1. Xue W,
    2. Zender L,
    3. Miething C, et al.
    Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 656–660. doi:10.1038/nature05529
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    1. Basisty N,
    2. Kale A,
    3. Jeon OH, et al.
    A proteomic atlas of senescence-associated secretomes for aging biomarker development. PLoS Biol 2020; 18: e3000599. www.dx.doi.org/10.1371/journal.pbio.3000599. doi:10.1371/journal.pbio.3000599
    OpenUrl
  38. ↵
    1. Desdín-Micó G,
    2. Soto-Heredero G,
    3. Aranda JF, et al.
    T cells with dysfunctional mitochondria induce multimorbidity and premature senescence. Science 2020; 368: 1371–1376. doi:10.1126/science.aax0860
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Hernandez-Segura A,
    2. de Jong T V,
    3. Melov S, et al.
    Unmasking Transcriptional Heterogeneity in Senescent Cells. Curr Biol 2017; 27: 2652–2660.e4. www.dx.doi.org/10.1016/j.cub.2017.07.033. doi:10.1016/j.cub.2017.07.033
    OpenUrlCrossRefPubMed
  40. ↵
    1. Xu M,
    2. Tchkonia T,
    3. Ding H, et al.
    JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc Natl Acad Sci U S A 2015; 112: E6301–E6310. doi:10.1073/pnas.1515386112
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Wilkinson JE,
    2. Burmeister L,
    3. Brooks S V, et al.
    Rapamycin slows aging in mice. Aging Cell 2012; 11: 675–682. doi:10.1111/j.1474-9726.2012.00832.x
    OpenUrlCrossRefPubMedWeb of Science
    1. Majumder S,
    2. Caccamo A,
    3. Medina DX, et al.
    Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and enhancing NMDA signaling. Aging Cell 2012; 11: 326–335. doi:10.1111/j.1474-9726.2011.00791.x
    OpenUrlCrossRefPubMedWeb of Science
    1. Mannick JB,
    2. Del Giudice G,
    3. Lattanzi M, et al.
    mTOR inhibition improves immune function in the elderly. Sci Transl Med 2014; 6: 268ra179. doi:10.1126/scitranslmed.3009892
    OpenUrlAbstract/FREE Full Text
    1. Laberge RM,
    2. Sun Y,
    3. Orjalo A V, et al.
    MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol 2015; 17: 1049–1061. doi:10.1038/ncb3195
    OpenUrlCrossRefPubMed
  42. ↵
    1. Mannick JB,
    2. Morris M,
    3. Hockey HU, et al.
    TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med 2018; 10: 1–11. doi:10.1126/scitranslmed.aaq1564
    OpenUrlPubMed
  43. ↵
    1. Moiseeva O,
    2. Deschênes-Simard X,
    3. St-Germain E, et al.
    Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation. Aging Cell 2013; 12: 489–498. doi:10.1111/acel.12075
    OpenUrlCrossRefPubMed
    1. Martin-Montalvo A,
    2. Mercken EM,
    3. Mitchell SJ, et al.
    Metformin improves healthspan and lifespan in mice. Nat Commun 2014; 4: 2192. doi:10.1038/ncomms3192
    OpenUrl
    1. Campbell JM,
    2. Bellman SM,
    3. Stephenson MD, et al.
    Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis. Ageing Res Rev 2017; 40: 31–44. www.doi.org/10.1016/j.arr.2017.08.003. doi:10.1016/j.arr.2017.08.003
    OpenUrlCrossRefPubMed
  44. ↵
    1. Bannister CA,
    2. Holden SE,
    3. Jenkins-Jones S, et al.
    Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab 2014; 16: 1165–1173. doi:10.1111/dom.12354
    OpenUrlCrossRefPubMed
    1. Zhang Q,
    2. Lenardo MJ,
    3. Baltimore D
    . 30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology. Cell 2017; 168: 37–57. www.dx.doi.org/10.1016/j.cell.2016.12.012. oi:10.1016/j.cell.2016.12.012
    OpenUrlCrossRefPubMed
  45. ↵
    1. Horwitz BH,
    2. Scott ML,
    3. Cherry SR, et al.
    Failure of lymphopoiesis after adoptive transfer of NF-κB-deficient fetal liver cells. Immunity 1997; 6: 765–772. doi:10.1016/S1074-7613(00)80451-3
    OpenUrlCrossRefPubMedWeb of Science
  46. ↵
    1. Nagashima K,
    2. Sasseville VG,
    3. Wen D, et al.
    Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKβ. Blood 2006; 107: 4266–4273. doi:10.1182/blood-2005-09-3852
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Park JM,
    2. Greten FR,
    3. Wong A, et al.
    Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis - CREB and NF-κB as key regulators. Immunity 2005; 23: 319–329. doi:10.1016/j.immuni.2005.08.010
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    1. Schmidt-Supprian M,
    2. Tian J,
    3. Ji H, et al.
    IκB Kinase 2 Deficiency in T Cells Leads to Defects in Priming, B Cell Help, Germinal Center Reactions, and Homeostatic Expansion. J Immunol 2004; 173: 1612–1619. doi:10.4049/jimmunol.173.3.1612
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Lavon I,
    2. Goldberg I,
    3. Amit S, et al.
    High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-κB activation. Nat Med 2000; 6: 573–577. doi:10.1038/75057
    OpenUrlCrossRefPubMedWeb of Science
  50. ↵
    1. Zhu Y,
    2. Tchkonia T,
    3. Pirtskhalava T, et al.
    The Achilles’ heel of senescent cells: From transcriptome to senolytic drugs. Aging Cell 2015; 14: 644–658. doi:10.1111/acel.12344
    OpenUrlCrossRefPubMed
    1. Roos CM,
    2. Zhang B,
    3. Palmer AK, et al.
    Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell 2016; 15: 973–977. doi:10.1111/acel.12458
    OpenUrlCrossRefPubMed
    1. Xu M,
    2. Pirtskhalava T,
    3. Farr JN, et al.
    Senolytics improve physical function and increase lifespan in old age. Nat Med 2018; 24: 1246–1256. www.dx.doi.org/10.1038/s41591-018-0092-9. doi:10.1038/s41591-018-0092-9
    OpenUrlCrossRef
    1. Lehmann M,
    2. Korfei M,
    3. Mutze K, et al.
    Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo. Eur Respir J 2017; 50: 1602367. doi:10.1183/13993003.02367-2016
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. Schafer MJ,
    2. White TA,
    3. Iijima K, et al.
    Cellular senescence mediates fibrotic pulmonary disease. Nat Commun 2017; 8: 14532. doi:10.1038/ncomms14532
    OpenUrlCrossRefPubMed
  52. ↵
    1. Justice JN,
    2. Nambiar AM,
    3. Tchkonia T, et al.
    Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine 2019; 40: 554–563. www.doi.org/10.1016/j.ebiom.2018.12.052. doi:10.1016/j.ebiom.2018.12.052
    OpenUrl
  53. ↵
    1. Hickson LTJ,
    2. Langhi Prata LGP,
    3. Bobart SA, et al.
    Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine 2019; 47: 446–456. doi:10.1016/j.ebiom.2019.08.069
    OpenUrl
  54. ↵
    1. Ahmad T,
    2. Sundar IK,
    3. Lerner CA, et al.
    Impaired mitophagy leads to cigarette smoke stress-induced cellular senescence: Implications for chronic obstructive pulmonary disease. FASEB J 2015; 29: 2912–2929. doi:10.1096/fj.14-268276
    OpenUrlCrossRefPubMed
  55. ↵
    1. Blázquez-Prieto J,
    2. Huidobro C,
    3. López-Alonso I, et al.
    Cellular senescence limits acute lung injury induced by mechanical ventilation. bioRxiv 2020.
    1. Parikh P,
    2. Britt RD,
    3. Manlove LJ, et al.
    Hyperoxia-induced cellular senescence in fetal airway smooth muscle cells. Am J Respir Cell Mol Biol 2019; 61: 51–60. doi:10.1165/rcmb.2018-0176OC
    OpenUrl
  56. ↵
    1. Klimova TA,
    2. Bell EL,
    3. Shroff EH, et al.
    Hyperoxia-induced premature senescence requires p53 and pRb, but not mitochondrial matrix ROS. FASEB J 2009; 23: 783–794. doi:10.1096/fj.08-114256
    OpenUrlCrossRefPubMedWeb of Science
  57. ↵
    1. Meyer KC,
    2. Ershler W,
    3. Rosenthal NS, et al.
    Immune Dysregulation in the Aging Human Lung. Am J Respir Crit Care Med 1996; 153: 1072–1079. doi:10.1164/ajrccm.153.3.8630547
    OpenUrlCrossRefPubMedWeb of Science
  58. ↵
    1. Tsuji T,
    2. Aoshiba K,
    3. Nagai A
    . Alveolar cell senescence exacerbates pulmonary inflammation in patients with chronic obstructive pulmonary disease. Respiration 2010; 80: 59–70. doi:10.1159/000268287
    OpenUrlCrossRefPubMedWeb of Science
  59. ↵
    1. Zhou F,
    2. Onizawa S,
    3. Nagai A, et al.
    Epithelial cell senescence impairs repair process and exacerbates inflammation after airway injury. Respir Res 2011; 12: 78. www.respiratory-research.com/content/12/1/78. doi:10.1186/1465-9921-12-78
    OpenUrlCrossRefPubMed
  60. ↵
    1. Müller KC,
    2. Welker L,
    3. Paasch K, et al.
    Lung fibroblasts from patients with emphysema showmarkers of senescence in vitro. Respir Res 2006; 7: 1–10. doi:10.1186/1465-9921-7-32
    OpenUrlCrossRefPubMedWeb of Science
  61. ↵
    1. Traves SL,
    2. Culpitt S V,
    3. Russell REK, et al.
    Increased levels of the chemokines GROα and MCP-1 in sputum samples from patients with COPD. Thorax 2002; 57: 590–595. doi:10.1136/thorax.57.7.590
    OpenUrlAbstract/FREE Full Text
    1. De Boer WI,
    2. Sont JK,
    3. Van Schadewijk A, et al.
    Monocyte chemoattractant protein I, interleukin 8, and chronic airways inflammation in COPD. J Pathol 2000; 190: 619–626. doi:10.1002/(SICI)1096-9896(200004)190:5<619::AID-PATH555>3.0.CO;2-6
    OpenUrlCrossRefPubMedWeb of Science
    1. Gessner C,
    2. Scheibe R,
    3. Wötzel M, et al.
    Exhaled breath condensate cytokine patterns in chronic obstructive pulmonary disease. Respir Med 2005; 99: 1229–1240. doi:10.1016/j.rmed.2005.02.041
    OpenUrlCrossRefPubMedWeb of Science
  62. ↵
    1. Aldera JK,
    2. Barkauskas CE,
    3. Limjunyawong N, et al.
    Telomere dysfunction causes alveolar stem cell failure. Proc Natl Acad Sci USA 2015; 112: 5099–5104. doi:10.1073/pnas.1504780112
    OpenUrlAbstract/FREE Full Text
  63. ↵
    1. Busse PJ,
    2. Birmingham JM,
    3. Calatroni A, et al.
    Effect of aging on sputum inflammation and asthma control. J Allergy Clin Immunol 2017; 139: 1808–1818.e6. doi:10.1016/j.jaci.2016.09.015
    OpenUrl
  64. ↵
    1. Hawkins GA,
    2. Robinson MB,
    3. Hastie AT, et al.
    IL-6R Variation Asp358Ala Is a Potential Modifier of Lung Function in Asthma. J Allergy Clin Immunol 2012; 130: 510–515. doi:10.1016/j.jaci.2012.03.018
    OpenUrlCrossRefPubMedWeb of Science
  65. ↵
    1. Kuwano K,
    2. Kunitake R,
    3. Kawasaki M, et al.
    P21Waf1/Cip1/Sdi1 and p53 Expression in Association With DNA Strand Breaks in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 1996; 154: 477–483. doi:10.1164/ajrccm.154.2.8756825
    OpenUrlCrossRefPubMedWeb of Science
    1. Lomas NJ,
    2. Watts KL,
    3. Akram KM, et al.
    Idiopathic pulmonary fibrosis: Immunohistochemical analysis provides fresh insights into lung tissue remodelling with implications for novel prognostic markers. Int J Clin Exp Pathol 2012; 5: 58–71.
    OpenUrlPubMed
    1. Álvarez D,
    2. Cárdenes N,
    3. Sellarés J, et al.
    IPF lung fibroblasts have a senescent phenotype. Am J Physiol Lung Cell Mol Physiol 2017; 313: L1164–L1173. doi:10.1152/ajplung.00220.2017
    OpenUrlCrossRefPubMed
  66. ↵
    1. Habermann A,
    2. Gutierrez A,
    3. Bui L, et al.
    Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis. Sci Adv 2020; 6: eaba1972. doi:10.1126/sciadv.aba1972
    OpenUrlFREE Full Text
  67. ↵
    1. Brandenberger C,
    2. Kling KM,
    3. Vital M, et al.
    The role of pulmonary and systemic immunosenescence in acute lung injury. Aging Dis 2018; 9: 553–565. doi:10.14336/AD.2017.0902
    OpenUrl
  68. ↵
    1. Palumbo S,
    2. Shin YJ,
    3. Ahmad K, et al.
    Dysregulated Nox4 ubiquitination contributes to redox imbalance and age-related severity of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2017; 312: L297–L308. doi:10.1152/ajplung.00305.2016
    OpenUrlCrossRefPubMed
  69. ↵
    1. Johnston CJ,
    2. Rubenfeld GD,
    3. Hudson LD
    . Effect of age on the development of ARDS in trauma patients. Chest 2003; 124: 653–659. www.dx.doi.org/10.1378/chest.124.2.653. doi:10.1378/chest.124.2.653
    OpenUrlCrossRefPubMedWeb of Science
  70. ↵
    1. Falsey AR,
    2. Walsh EE
    . Respiratory syncytial virus infection in elderly adults. Drugs Aging 2005; 22: 577–587. doi:10.2165/00002512-200522070-00004
    OpenUrlCrossRefPubMed
    1. Pop-Vicas A,
    2. Gravenstein S
    . Influenza in the elderly - A mini-review. Gerontology 2011; 57: 397–404.
    OpenUrlPubMed
  71. ↵
    1. Chen J,
    2. Kelley WJ,
    3. Goldstein DR
    . Role of Aging and the Immune Response to Respiratory Viral Infections: Potential Implications for COVID-19. J Immunol 2020; 205: 313–320. www.ncbi.nlm.nih.gov/pubmed/32493812. doi:10.4049/jimmunol.2000380
    OpenUrlAbstract/FREE Full Text
    1. Baas T,
    2. Roberts A,
    3. Teal TH, et al.
    Genomic Analysis Reveals Age-Dependent Innate Immune Responses to Severe Acute Respiratory Syndrome Coronavirus. J Virol 2008; 82: 9465–9476. doi:10.1128/JVI.00489-08
    OpenUrlAbstract/FREE Full Text
  72. ↵
    1. Onder G,
    2. Rezza G,
    3. Brusaferro S
    . Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA 2020: 323: 1775–1776. www.ncbi.nlm.nih.gov/pubmed/32203977.
    OpenUrlPubMed
  73. ↵
    1. Zhou F,
    2. Yu T,
    3. Du R, et al.
    Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 6736: 1–9.
    OpenUrlCrossRefPubMed
  74. ↵
    1. Chou J P,
    2. Effros R B
    . T Cell Replicative Senescence in Human Aging. Curr Pharm Des 2013; 19: 1680–1698.
    OpenUrlCrossRefPubMed
    1. Shaw AC,
    2. Joshi S,
    3. Greenwood H, et al.
    Aging of the innate immune system. Curr Opin Immunol 2010; 22: 507–513. doi:10.1016/j.coi.2010.05.003
    OpenUrlCrossRefPubMedWeb of Science
  75. ↵
    1. Dorrington MG,
    2. Bowdish DME
    . Immunosenescence and novel vaccination strategies for the elderly. Front Immunol 2013; 4: 1–10. doi:10.3389/fimmu.2013.00171
    OpenUrlCrossRefPubMed
  76. ↵
    1. Aiello A,
    2. Farzaneh F,
    3. Candore G, et al.
    Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention. Front Immunol 2019; 10: 2247. doi:10.3389/fimmu.2019.02247
    OpenUrl
    1. Nikolich-Žugich J
    . The twilight of immunity: Emerging concepts in aging of the immune system review-article. Nat Immunol 2018; 19: 10–19. doi:10.1038/s41590-017-0006-x
    OpenUrlCrossRefPubMed
  77. ↵
    1. Barbé-Tuana F,
    2. Funchal G,
    3. Schmitz CRR, et al.
    The interplay between immunosenescence and age-related diseases. Semin Immunopathol 2020: 1–13.
  78. ↵
    1. Appay V,
    2. Almeida JR,
    3. Sauce D, et al.
    Accelerated immune senescence and HIV-1 infection. Exp Gerontol 2007; 42: 432–437. doi:10.1016/j.exger.2006.12.003
    OpenUrlCrossRefPubMedWeb of Science
  79. ↵
    1. Voehringer D,
    2. Blaser C,
    3. Brawand P, et al.
    Viral Infections Induce Abundant Numbers of Senescent CD8 T Cells. J Immunol 2001; 167: 4838–4843. doi:10.4049/jimmunol.167.9.4838
    OpenUrlAbstract/FREE Full Text
  80. ↵
    1. Baz-Martínez M,
    2. Da Silva-Álvarez S,
    3. Rodríguez E, et al.
    Cell senescence is an antiviral defense mechanism. Sci Rep 2016; 6: 1–11. www.dx.doi.org/10.1038/srep37007. doi:10.1038/s41598-016-0001-8
    OpenUrlCrossRefPubMed
  81. ↵
    1. Kulkarni U,
    2. Zemans RL,
    3. Smith CA, et al.
    Excessive neutrophil levels in the lung underlie the age-associated increase in influenza mortality. Mucosal Immunol 2019; 12: 545–554. www.dx.doi.org/10.1038/s41385-018-0115-3. doi:10.1038/s41385-018-0115-3
    OpenUrl
  82. ↵
    1. Ivashkiv LB,
    2. Donlin LT
    . Regulation of type I interferon responses. Nat Rev Immunol 2014; 14: 36–49. doi:10.1038/nri3581
    OpenUrlCrossRefPubMed
  83. ↵
    1. Kuilman T,
    2. Michaloglou C,
    3. Vredeveld LCW, et al.
    Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network. Cell 2008; 133: 1019–1031. doi:10.1016/j.cell.2008.03.039
    OpenUrlCrossRefPubMedWeb of Science
  84. ↵
    1. Ritschka B,
    2. Storer M,
    3. Mas A, et al.
    The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration. Genes Dev 2017; 31: 172–183. doi:10.1101/gad.290635.116
    OpenUrlAbstract/FREE Full Text
  85. ↵
    1. Chuprin A,
    2. Gal H,
    3. Biron-Shental T, et al.
    Cell fusion induced by ERVWE1 or measles virus causes cellular senescence. Genes Dev 2013; 27: 2356–2366. doi:10.1101/gad.227512.113
    OpenUrlAbstract/FREE Full Text
  86. ↵
    1. Moiseeva O,
    2. Mallette FA,
    3. Mukhopadhyay UK, et al.
    DNA Damage Signaling and p53-dependent Senescence after Prolonged B-Interferon Stimulation. Mol Biol Cell 2006; 17: 5356-1583–1592. doi:10.1091/mbc.e05-09-0858
    OpenUrl
  87. ↵
    1. Yu Q,
    2. Katlinskaya Y V,
    3. Carbone CJ, et al.
    DNA damage-induced type I interferon promotes senescence and inhibits stem cell function. Cell Rep 2015; 11: 785–797. doi:10.1016/j.celrep.2015.03.069
    OpenUrlCrossRefPubMed
  88. ↵
    1. Oishi N,
    2. Shilagardi K,
    3. Nakamoto Y, et al.
    Hepatitis B virus X protein overcomes oncogenic RAS-induced senescence in human immortalized cells. Cancer Sci 2007; 98: 1540–1548. doi:10.1111/j.1349-7006.2007.00579.x
    OpenUrlCrossRefPubMed
  89. ↵
    1. DiPaolo JA,
    2. Popescu NC,
    3. Alvarez L, et al.
    Cellular and molecular alterations in human epithelial cells transformed by recombinant human papillomavirus. Crit Rev Oncog 1993; 4: 337–360.
    OpenUrlPubMedWeb of Science
  90. ↵
    1. Persson BD,
    2. Jaffe AB,
    3. Fearns R, et al.
    Respiratory syncytial virus can infect basal cells and alter human airway epithelial differentiation. PLoS One 2014; 9: 1–15.
    OpenUrlCrossRefPubMed
  91. ↵
    1. Kim JA,
    2. Seong RK,
    3. Shin OS
    . Enhanced viral replication by cellular replicative senescence. Immune Netw 2016; 16: 286–295. doi:10.4110/in.2016.16.5.286
    OpenUrlCrossRef
  92. ↵
    1. Josset L,
    2. Engelmann F,
    3. Haberthur K, et al.
    Increased Viral Loads and Exacerbated Innate Host Responses in Aged Macaques Infected with the 2009 Pandemic H1N1 Influenza A Virus. J Virol 2012; 86: 11115–11127. doi:10.1128/JVI.01571-12
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
View this article with LENS
Vol 57 Issue 2 Table of Contents
European Respiratory Journal: 57 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cellular Senescence: Friend or Foe to Respiratory Viral Infections?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Cellular Senescence: Friend or Foe to Respiratory Viral Infections?
William J. Kelley, Rachel L. Zemans, Daniel R. Goldstein
European Respiratory Journal Jan 2020, 2002708; DOI: 10.1183/13993003.02708-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Cellular Senescence: Friend or Foe to Respiratory Viral Infections?
William J. Kelley, Rachel L. Zemans, Daniel R. Goldstein
European Respiratory Journal Jan 2020, 2002708; DOI: 10.1183/13993003.02708-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Cellular Senescence: Definition and Evolutionary Origins
    • What leads to senescence and the resulting Senescence Associated Secretory Phenotype (SASP)
    • Senescence-Targeted Therapeutics
    • Cellular Senescence in the Lung
    • Cellular Senescence and Respiratory Viral Infections
    • Cellular Senescence: Friend or Foe in Respiratory Viral Infections?
    • Conclusions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Framework for the evaluation of new tests for tuberculosis infection
  • Sleep Laboratories Reopening and COVID-19: A European Perspective
Show more Perspective

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society